{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001183","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.857579+00:00","generated_at":"2026-05-25T16:48:57.823691+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cassava Sciences Reports 2024 Financial Results and Provides Business Update","bullets":["Net loss of $24.3 million ($0.53 per share) in 2024 vs $97.2 million in 2023; cash and equivalents $128.6 million with no debt.","Top-line data for REFOCUS-ALZ, second Phase 3 study of simufilam in Alzheimer's, expected late Q1/early Q2 2025.","RETHINK-ALZ Phase 3 study did not meet co-primary endpoints in November 2024; all Alzheimer's clinical studies discontinued.","License agreement with Yale University to explore simufilam for seizures related to tuberous sclerosis complex (TSC).","G&A expenses rose to $71.8 million in 2024 due to $40 million SEC settlement and higher stock-based compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001183","json":"https://secwatch.observer/filing/0001171843-25-001183.json","markdown":"https://secwatch.observer/filing/0001171843-25-001183.md","text":"https://secwatch.observer/filing/0001171843-25-001183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325001183/0001171843-25-001183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325001183/f8k_030325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-25T16:48:57.823691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}